15 December 2021
Apollon Formularies Completes High-Volume Processing Laboratory
In Preparation for International Export of Medical Cannabis Products
• Apollon Formularies completes state-of-the-art high-volume processing laboratory
• Increased processing capacity to 20 Litres per day of analytically validated medical cannabis oil
• Apollon to significantly increase its inventory in preparation for global export
• Increased capacity provides readily available inventory for potential pharmaceutical partners to perform independent clinical trial validation
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a
Apollon's proprietary medical cannabis products were recently shown in pre-clinical 3rd party, independent testing at BIOENSIS laboratories in
Apollon's medical cannabis products are now available to patients by physician prescription and for clinical trials at the International Cancer and Chronic Pain Institute in
According to a recently published Allied Market Research report, the global medical cannabis industry generated
The oil segment held the largest revenue share in the cannabis extract market and was valued at
"There is an increasing global demand for medical cannabis oils, and I believe the oils that will be most sought after will be those that have been validated in pre-clinical and clinical patent data that demonstrates successful results and not just random generic oils with no clinical testing. " stated Stephen D. Barnhill, MD, Chairman and CEO of Apollon Formularies, plc, "Our goal, as a Cannabis Licensing Authority (CLA) licensed processing facility, is to produce large amounts of the highest quality medicinal cannabis products with demonstrated successful clinical results for the medical patients in
Dr. Herbert Fritsche, Apollon's Chief Science Officer, and Former Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at the University of
Director of Research Development and Communications at the Cannabis Licensing Authority (CLA), Felicia Bailey, says the agency is committed to facilitating the import and export of cannabis until the import/export regulations are promulgated. Under the Interim Measures, licensees can export cannabis inflorescence/buds and extracts from
Jeff Nagel, Director of Processing and Product Manufacturing for Apollon, commented, "I want to congratulate our extraction team for their efforts in completing this new state-of-the-art processing laboratory and their dedication to producing the highest quality medical cannabis oils for our patients", Mr. Nagel continued, "The Jamaican landrace strains are giving us a very nice spectrum of not only THC and CBD but high levels of minor cannabinoids such as CBC, CBG and THCV for our medical cannabis formulations."
On 19 July 2021, Apollon announced that its proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures by direct cytotoxicity.
June 28, 2021, Apollon announced that its proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing triple-negative breast cancer cells in 3D cell culture by direct cell cytotoxicity.
May 18, 2021, Apollon announced that its proprietary medical cannabis formulations were shown in third party independent clinical laboratory testing to be effective in killing HER2+ breast cancer cells in 3D cell culture by direct cytotoxicity.
The Directors of the Company accept responsibility for the contents of this announcement.
For additional information, please visit www.apollon.org.uk or contact:
Tel: +44 207 907 9314
Stene Jacobs email@example.com
Peterhouse Capital Limited (Corporate Adviser)
Tel: +44 207 220 9795
Guy Miller firstname.lastname@example.org
Blytheweigh (Financial PR/IR-London)
Tel: +44 207 138 3204
Tim Blythe email@example.com
Megan Ray firstname.lastname@example.org
About Apollon and Apollon Jamaica
Apollon Formularies plc is an international medical cannabis company headquartered in the United Kingdom. Apollon Formularies Jamaica, Ltd is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica and a contractual affiliate of Apollon. Apollon Jamaica is licensed by the Jamaican government's Cannabis Licensing Authority (CLA) to purchase cannabis under tripartite agreements from licensed cultivators, process, perform research and development, and sell medical cannabis therapeutic products that include legal medical cannabis in order to treat various illnesses under medical supervision.